Innovent Biologics

Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy

SINTBILO® (tafolecimab injection) monotherapy achieved significant reduction of LDL-C level, with > 60% mean LDL-C reduction after 12 weeks of…